Effect of Proton Pump Inhibitor Therapy on NOX5, mPGES1 and iNOS expression in Barrett’s Esophagus

Dan Li1,4, Deepthi Deconda3,4, Aihua Li1, Fadlallah Habr1* & Weibiao Cao1,2*

Acid reflux may contribute to the progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EA). However, it is not clear whether the molecular changes present in BE patients are reversible after proton pump inhibitor (PPI) treatment. In this study we examined whether PPI treatment affects NOX5, microsomal prostaglandin E synthase (mPGES)-1 and inducible nitric oxide synthase (iNOS) expression. We found that NADPH oxidase 5 (NOX5), mPGES-1 and iNOS were significantly increased in BE mucosa. One-month PPI treatment significantly decreased NOX5, mPGES1 and iNOS. In BAR-T cells, NOX5 mRNA and p16 promoter methylation increased after pulsed acid treatment in a time-dependent manner. Four or eight-week-acid induced increase in NOX5 mRNA, NOX5 protein and p16 methylation may be reversible. Twelve-week acid treatment also significantly increased NOX5, mPGES1 and iNOS mRNA expression. However, twelve-week-acid-induced changes only partially restored or did not recover at all after the cells were cultured at pH 7.2 for 8 weeks. We conclude that NOX5, mPGES1 and iNOS may be reversible after PPI treatment. Short-term acid-induced increase in NOX5 expression and p16 methylation might be reversible, whereas long-term acid-induced changes only partially recovered 8 weeks after removal of acid treatment.

How the progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EA) occurs is not fully understood. We have reported that NOX5-S is identifiable in Barrett’s cells BAR-T and EA cells FLO-1 and OE331,2 and is significantly increased in FLO-1 cells and EA tissues3. NOX5-S mRNA is also elevated in Barrett’s mucosa with high-grade dysplasia4. NOX5-S expression and H2O2 production are significantly enhanced in response to pulsed acid treatment in BAR-T and OE33 cells1 and Barrett’s mucosa4. These data suggest that NOX5-S may be responsible for the overproduction of reactive oxygen species (ROS) in BE and in EA cells. How NOX5-S is upregulated in EA cells is not known. Multiple factors may contribute to it, e.g. acid, bile acid, acid/bile acid reflux-induced inflammation, and others. We have reported that Rho kinase, ERK1/2 MAP kinases and cAMP response element binding protein are involved in acid-induced increase in NOX5-S expression4,5. Platelet activating factor, which may be produced after acid exposure, may activate signal transducer and activator of transcription 5 (STAT5) and then upregulate NOX5-S6. NOX5-S may play an important role in acid-induced increase in cell proliferation in Barrett’s cells BAR-T and EA cells (OE33 and FLO-1)6,7. NOX5-S-mediated increase in cell proliferation may be dependent on the activation of COX24 and microsomal prostaglandin E synthase 1 (mPGES1)7, and on the reduction of p16 via promoter methylation1. NOX5-S may also be involved in the acid-induced DNA damage8. These data suggest that persistent acid reflux present in BE patients may significantly increase NOX5-S expression, ROS production, cell proliferation and DNA damage, thereby contributing to the progression from BE to dysplasia and to EA. These data suggest that reactive oxygen species may be important in this progression. However, whether NOX5 is reversible upon PPI treatment is not known.

COX-2-derived prostaglandin E2 may also contribute to the progression from BE to EA since (1) PGE2 increases cell proliferation, promoter methylation and tumor growth9; (2) selective COX-2 inhibitors may prevent EA development in a rat model of BE10. PGE2 is produced by PG synthase (PGES), which has three
isoforms: a cytosolic (cPGES) and two microsomal (mPGES) isomerase isoforms. mPGES1 has been reported to be increased in an animal model of BE and in human EA. We have also reported that mPGES1 is identifiable in FLO-1 EA cells and that mPGES1 mRNA and protein levels are significantly enhanced in response to pulsed acid treatment in FLO-1 cells. Therefore, mPGES1 may also contribute to the development of EA. It is not known whether PPI treatment may reverse mPGES1.

It is known that nitric oxide (NO) is involved in angiogenesis, apoptosis, gene expression, and DNA damage and may be important in carcinogenesis and tumor progression in the gastrointestinal tract. NO may produce peroxynitrite and N2O3 when it reacts with the superoxide radical and oxygen, respectively. Three isoforms of NO synthase have been identified: endothelial NO synthase (NOS), neuronal NOS and inducible NOS. Large amount of NO may be generated by inducible NOS during inflammation and may in part mediate the progression from BE to EA.

Our aim in this study is to examine NOX5, mPGES1 and iNOS in BE and to investigate whether PPI treatment reverses these genes. We found that NOX5, mPGES1 and iNOS were significantly increased in BE mucosa. PPI treatment for one month significantly decreased all three genes.

Results
NADPH oxidases in BE mucosa. Eight male BE patients aged from 58 to 75 (average 67.5 ± 2.3) were enrolled in this study. The duration of the disease was 3–17 years (11.2 ± 2.1 years). The length of the BE was 2–11 cm (4.6 ± 1 cm). BE patients were asked to discontinue PPI for one month and then the first biopsy was obtained. After the first biopsy, the treatment with proton pump inhibitor (PPI) was started twice a day for one month. At the end of this one-month period of PPI treatment, biopsies were repeated.

Figure 1 showed that NOX5 mRNA was significantly increased in BE mucosa, when compared with normal esophageal mucosa. Dual oxidase 1 (DUOX1) and DUOX2 mRNAs did not have significant changes between BE mucosa and normal esophageal mucosa. PPI treatment for a month significantly decreased NOX5 mRNA. The data suggest that the increased NOX5 mRNA may be reversible in BE mucosa after PPI treatment. N = 5; ANOVA *P < 0.05, compared normal, **P < 0.05, compared with BE without PPI.
Microsomal PGE synthase 1 in BE mucosa. We have previously reported that mPGES1 is identifiable in FLO-1 EA cells and is increased in response to pulsed acid treatment7. Figure 3A showed that mPGES1 mRNA was significantly increased in BE mucosa, an increase which was significantly attenuated by PPI treatment, suggesting that mPGES1 may be reversible in BE mucosa after PPI treatment. PPI did not have any effect on mPGES1 in normal esophageal mucosa (Fig. 2B).

Inducible nitric oxide synthase in BE mucosa. Inducible NOS expression has been shown to be gradually upregulated in the progression from BE to EA, but not in normal esophageal/gastric mucosa20,21. We found that inducible NOS was significantly increased in the BE mucosa, an increase which was significantly reduced by PPI treatment (Fig. 3B), suggesting that the overexpression of iNOS might be reversible in BE mucosa after PPI treatment. PPI did not have any effect on iNOS in normal esophageal mucosa (Fig. 2C).

Effect of omeprazole on NOX5, mPGES1 and iNOS expression in Barrett's EA cells. Barrett's EA cell line FLO-1 was treated with omeprazole 1 μM for 24 hours and then mRNAs were measured by real-time PCR. Figure 4 showed that omeprazole had no effect on NOX5, mPGES1 and iNOS mRNA expression.

Effect of long-term acid treatment on NOX5-S expression, p16 promoter methylation, mPGES1 and iNOS expression. We have previously shown that NADPH oxidase NOX5-S exists in FLO-1 EA cells and that it is upregulated in Barrett's mucosa with high-grade dysplasia and responsible for the acid-induced ROS production4.

To examine whether the overexpression of NOX5-S is reversible, BAR-T cells were first treated with acidic culture medium (pH 4.0) for 5 min, three times a day for 2, 4, 8 and 12 weeks. Then BAR-T cells were cultured at normal culture medium (pH 7.2) for additional 2, 4 and 8 weeks after acid treatment for 2, 4, 8 and 12 weeks, respectively. Figure 5A showed that NOX5 mRNA increased after pulsed acid treatment in a time-dependent manner. Figure 5B and 5c showed that the increase in NOX5 mRNA induced by pulsed acid treatment for 4 and 8 weeks almost recovered after cells were cultured in normal culture medium for 8 weeks. However, 12-week-acid-induced increase in NOX5 mRNA only partially restored after the cells were cultured in normal culture medium for 8 weeks (Fig. 5D). Similarly, pulsed acid treatment for 4 and 12 weeks significantly increased NOX5-S protein levels. The increase in NOX5-S protein induced by pulsed acid treatment for 4 weeks almost recovered after the cells were cultured in normal culture medium for 8 weeks. However, 12-week-acid-induced increase in NOX5 protein only partially restored after the cells were cultured in normal culture medium for 8 weeks (Fig. 6). These data suggest that, if BAR-T cells exposed to pulsed acid treatment for a longer period, the cells would take a much longer time to recover.

Similarly, p16 promoter methylation increased after pulsed acid treatment in a time-dependent manner (Fig. 7A). This increase in p16 promoter methylation induced by pulsed acid treatment for 4 and 8 weeks almost recovered after the cells were cultured in normal culture medium for 8 weeks (Fig. 7B,C). However, 12-week-acid-induced increase in p16 promoter methylation did not restore after the cells were cultured in normal culture medium for 8 weeks (Fig. 7D). In addition, twelve-week acid treatment significantly increased mPGES1 and iNOS mRNA expressions (Fig. 8). These increases did not restore after the cells were cultured in normal culture medium for 8 weeks. These data suggest that long-term acid treatment may cause irreversible gene changes.

Figure 3. Expression of mPGES1 and iNOS. (A) mPGES1 mRNA was significantly increased in BE mucosa, an increase which was significantly decreased by PPI treatment, suggesting that mPGES1 may be reversible in BE mucosa by PPI treatment. (B) Inducible NOS was significantly increased in the BE mucosa, an increase which was significantly reduced by PPI treatment, suggesting that the overexpression of iNOS might be reversible. N = 5; ANOVA *P < 0.02, compared normal, **P < 0.05, compared with BE without PPI.
Figure 4. Effect of omeprazole on NOX5, mPGES1 and iNOS in FLO-1 cells. FLO-1 cells were treated with omeprazole 1 μM for 24 hours and then mRNAs were measured by real-time PCR. (A) Omeprazole had no effect on NOX5 mRNA. (B) Omeprazole had no effect on mPGES1 mRNA. (C) Omeprazole had no effect on iNOS mRNA.

Figure 5. Effect of long-term acid treatment on NOX5-S mRNA expression. BAR-T cells were first treated with acidic culture medium (pH 4.0) for 5 min, three times a day for 2, 4, 8 and 12 weeks. Then BAR-T cells were cultured at normal culture medium (pH 7.2) for additional 2, 4 and 8 weeks after acid treatment for 2, 4, 8 and 12 weeks, respectively. (A) NOX5 mRNA increased after pulsed acid treatment in a time-dependent manner. (B) The increase in NOX5 mRNA induced by pulsed acid treatment for 4 weeks almost completely recovered after the cells were cultured in normal culture medium for 4–8 weeks. (C) The increase in NOX5 mRNA induced by pulsed acid treatment for 8 weeks almost completely recovered after the cells were cultured in normal culture medium for 8 weeks. (D) 12-week-acid-induced increase in NOX5 mRNA only partially restored after cells were cultured in normal culture medium for 8 weeks. These data suggest that, if BAR-T cells exposed to pulsed acid treatment for a longer period of time, the cells would take a much longer time to recover. N = 3, ANOVA. *P < 0.01, **P < 0.001, compared with control, #P < 0.05, ##P < 0.01 compared with acid group.
Discussion

We have previously reported that NOX5-S is responsible for the increase in cell proliferation in response to acid treatment in Barrett’s cells BAR-T and EA cells (OE33 and FLO-1) and is involved in acid-induced DNA damage. In this study we examined whether PPI reverses oxidative stress genes.

We found that NOX5 and iNOS were markedly elevated in BE mucosa. We have previously reported that NOX5-S is the major isoform of NADPH oxidases in FLO-1 EA cells. The increase of NOX5 and iNOS may increase the production of ROS and thereby cause gene damage. Reactive oxygen species may increase gene mutation and modify the functions of enzyme and proteins (e.g. activation of oncogene products and/or inhibition of tumor suppressor proteins) via the damage of DNA, RNA, lipids and proteins. Microsomal PGES1 mRNA was also significantly increased in BE mucosa. Similarly, pulsed acid treatment significantly enhanced the expressions of NOX5, iNOS, and mPGES1 mRNAs in BAR-T cells.

We also found that NOX5, mPGES1 and iNOS may be reversible in BE mucosa after PPI treatment. PPI treatment significantly downregulated the NOX5 mRNA, mPGES1 mRNA and iNOS mRNA expression. However, PPI did not affect these gene expression in normal esophageal mucosa.

To further confirm these in vivo data, we examined whether the overexpression of NOX5-S and hypermethylation of p16 may be reversible in vitro. We found that short-term (such as 4 weeks) acid-induced increase in NOX5 mRNA and p16 promoter methylation may be reversible since the increase in NOX5 mRNA and p16 methylation induced by pulsed acid treatment for 4 and 8 weeks almost completely recovered after the cells were cultured in normal culture medium for 8 weeks. However, long-term (such as 12 weeks) acid treatment-induced increase in NOX5 mRNA, iNOS, mPGES1, and p16 methylation may take more than 8 weeks to recover since these genes were not restored after the cells were cultured in normal culture medium for 8 weeks.

PPI has both anti-acid secretion and anti-inflammatory effects. Our in vitro data suggest that inhibition of acid reflux by PPI may be involved in the reversal of NOX5, mPGES1 and iNOS in vivo since 1) short-term (such as 4 weeks) acid-induced increase in NOX5 mRNA and p16 promoter methylation was recovered after removal of acid treatment; 2) Omeprazole did not have any effect on the expression of NOX5, mPGES1 and iNOS in cultured FLO-1 cells.

In conclusion, NOX5, mPGES1 and iNOS were significantly increased in BE mucosa. Proton pump inhibitor treatment for one month significantly decreased these three gene expression. In BAR-T cells, NOX5 mRNA, iNOS mRNA, mPGES1 mRNA and p16 promoter methylation increased after pulsed acid treatment. Four or

---

**Figure 6.** Effect of long-term acid treatment on NOX5-S protein expression. BAR-T cells were first treated with acidic culture medium (pH 4.0) for 5 min, three times a day for 4 and 12 weeks. Then BAR-T cells were cultured at normal culture medium (pH 7.2) for additional 8 weeks. (A) Typical image of three Western blot analysis and (B) Summarized data showed that the increase in NOX5 protein induced by pulsed acid treatment for 4 weeks almost completely recovered after the cells were cultured at normal culture medium for 8 weeks. (C) Typical image of three Western blot analysis and (D) summarized data showed that the increase in NOX5 protein induced by pulsed acid treatment for 12 weeks only partially restored after the cells were cultured at normal culture medium for 8 weeks. These data suggest that, if BAR-T cells exposed to pulsed acid treatment for a longer period, the cells would take a much longer time to recover. N = 3, ANOVA. *P < 0.01, compared with control. **P < 0.01 compared with acid group. Original Western blot images are available in the supplemental file at https://doi.org/10.1038/s41598-019-52800-7.
Figure 7. Effect of long-term acid treatment on p16 methylation (A). p16 promoter methylation increased after pulsed acid treatment in a time-dependent manner. (B) This increase in p16 promoter methylation induced by pulsed acid treatment for 4 weeks almost completely recovered after cells were cultured in normal culture medium for 4–8 weeks. (C) The increase in p16 promoter methylation induced by pulsed acid treatment for 8 weeks almost completely recovered after the cells were cultured in normal culture medium for 8 weeks. (D) 12-week-acid induced increase in p16 promoter methylation did not restore after the cells were cultured in normal culture medium for 8 weeks. N = 3, ANOVA, *P < 0.05, **P < 0.01, compared with control; #P < 0.05, ##P < 0.01, compared with acid group.

Figure 8. Effect of long-term acid treatment on mPGES1 and iNOS mRNA expression. BAR-T cells were first treated with acidic culture medium (pH 4.0) for 5 min, three times a day for 12 weeks. Then BAR-T cells were cultured at normal culture medium (pH 7.2) for additional 8 weeks after acid treatment for 12 weeks. (A) 12-week acid treatment significantly increased mPGES1 mRNA. The increase did not restore after the cells were cultured in normal culture medium for 8 weeks. (B) 12-week acid treatment significantly increased iNOS mRNA. The increase did not restore after the cells were cultured in normal culture medium for 8 weeks. ANOVA. *P < 0.05, compared with control.
eight-week-acid induced increase in NOX5 mRNA and p16 methylation may be reversible. However, twelve-week acid-induced increase in NOX3 mRNA, iNOS mRNA, mPGES1 mRNA and p16 methylation only partially recovered 8 weeks after removal of acid treatment. Our data imply that early PPI treatment might be important in the prevention of the irreversible molecular changes induced by acid reflux.

Methods

PPI treatment and esophageal biopsies. Eight male BE patients aged from 58 to 75 (average 67.5 ± 2.3) were enrolled in this study. The duration of the disease was 3–17 years (11.2 ± 2.1 years). The length of the BE was 2–11 cm (4.6 ± 1 cm). First biopsy was obtained after the patients discontinued PPI for one month. Four specimens every 2 centimeters were obtained within the length of the Barrett’s esophagus. Biopsies from the normal-looking squamous mucosa of the upper esophagus (approximately 10 cm above BE) were used as control. Then the treatment with proton pump inhibitor (PPI) omeprazole was started 40 mg, twice a day for one month. At the end of this one-month period of PPI treatment, biopsies were repeated. The experimental protocols were approved by the Human Research Institutional Review Committee at Rhode Island Hospital and at Providence VA hospital. All research was performed in accordance with relevant guidelines and informed consent was obtained from all participants.

Cell culture. Human Barrett’s cell line BAR-T25, provided to us by Dr. Rhonda Souza (University of Texas Southwestern Medical Center, Texas), was cultured in Keratinocyte Medium-2 (Ca2+-free solution, Cambrex, Rockland, ME) supplemented with 1.8 mM CaCl2 and other agents as we previously reported1. For acid treatment, BAR-T cells were treated with acidic culture medium (pH 4.0) for 5 min, three times a day for 2, 4, 8 and 12 weeks. Cells were collected after acid treatment. To examine whether the molecular changes are reversible, cells were cultured at normal culture medium (pH 7.2) for additional 2, 4 and 8 weeks after acid treatment for 2, 4, 8 and 12 weeks, respectively.

BE EA cell line FLO-1 was generously provided to us by Dr. David Beer (University of Michigan). FLO cells were cultured in DMEM containing 10% fetal bovine serum and antibiotics. For PPI treatment, FLO-1 cells were treated with omeprazole 1 μM for 24 hours.

Reverse transcription-PCR. Total RNA from esophageal biopsies was purified by using The RNeasy Micro Kit (Qiagen, Germantown, MD). TRIZol reagent (ThermoFisher Scientific, Foster City, CA) was used to purify total RNA from the cultured cells and GeneAmp Gold RNA PCR reagent kit (ThermoFisher Scientific, Foster City, CA) was utilized to reversely transcribe 1.5 μg of total RNAs.

PCR array. 96-well PCR array was performed by using Human Oxidative Stress PCR Array (Qiagen) according to the manufacturer’s protocol. Data were analyzed by using Qiagen web-based software. All the data were normalized by five house-keeping genes.

Quantitative real-time PCR. Real-time PCR was performed as we previously described15,28. The primers used were: NOX5-S sense (5′-AAGACCTCATACGGGGCTGCA-3′), NOX5-S antisense (5′-CTTTGACCACTTGGCCAGA-3′); iNOS sense (5′-AGTGACGAGATGACCTCAG-3′)29; iNOS antisense (5′-GGGTTGCGATCCAGTTGACCA-3′); mPGES1 sense (5′-GGGTTGCGATCCAGTTGACCA-3′); mPGES1 antisense (5′-GACTGTGACAAAGACATCCA-3′); 18S sense (5′-GGGTTGCGATCCAGTTGACCA-3′) and 18S antisense (5′-TGGAGGAAGACCTTAGGTTGACCA-3′) and 18S antisense (5′-GGGTTGCGATCCAGTTGACCA-3′). Reactions were carried out in an Applied Biosystems StepOnePlus™ Real-Time PCR System for 40 cycles at 95 °C for 45 s, 58 °C for 50 s, and 72 °C for 50 s.

Bisulfite conversion of DNA sample. A CpG modification Kit (EZ DNA methylation-Direct™ Kit, Zymo Research, CA) was used to convert genomic DNA according to the manufacturer’s protocol and as we previously described1.

Conventional methylation specific PCR (MSP). MSP was performed as we previously described1. The primers for the bisulfite-converted methylated sequence were p16MF:5′-TTTATTAGAGGTTGGGCGGATGC-3′ and p16MR:5′-GACCCCCGAGGCGGATGC-3′. The primers for the bisulfite-converted unmethylated sequence were p16UF:5′-TTTATTAGAGGTTGGGCGGATGC-3′ and p16UR:5′-CAACCCCACACCAACACATTA-3′.

Real-Time Quantitative Methylation Specific PCR was performed as we previously described3. Methylated p16 gene was detected by using primers p16MF and p16MR. β-actin served as a control. Primers for β-actin were: β-actin-F: 5′-TGGTATGGAGGGTTTGAGTAT-3′ and β-actin-R: 5′-AACCAATAAAAACCTACTCTCCTAAG-3′. 40 cycles of PCR were run at 95 °C 30 s, 60 °C for 30 s and 72 °C for 30 s.

Western blot analysis. Western blot analysis was performed as described previously28. The NOX5 antibody was generously provided to us by Dr. David Lambeth27 and used at a dilution of 1:1000. The same membrane was used to probe GAPDH. The GAPDH antibody was used at a dilution of 1:1000.

Statistical analysis. Data were expressed as mean ± S.E. Analysis of variance (ANOVA) was used to test statistical differences among multiple groups and Fisher’s protected least significant difference test was utilized to check significance.

Received: 13 May 2019; Accepted: 10 October 2019;
Published online: 07 November 2019
References
1. Hong, J. et al. Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. *Am J Physiol Gastrointest Liver Physiol* **299**, G697–706, doi:10.1152/ajpgi.00186.2010.
2. Hong, J. et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. *Gut* **59**, 170–180, doi:10.1136/gut.2009.183875.
3. Hong, J. et al. Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells. *Am J Physiol Cell Physiol* **301**, C413–420, doi:10.1152/ajpcell.00027.2011.
4. Fu, X. et al. cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells. *J Biol Chem* **281**, 20368–20382 (2006).
5. Hong, J., Li, D. & Cao, W. Rho Kinase ROCK2 Mediates Acid-Induced NADPH Oxidase NOX5-S Expression in Human Esophageal Adenocarcinoma Cells. *PLoS One* **11**, e0149735, https://doi.org/10.1371/journal.pone.0149735 (2016).
6. Si, J. et al. STAT5 mediates PAF-induced NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells. *Am J Physiol Gastrointest Liver Physiol* **294**, G174–183 (2008).
7. Zhou, X., Li, D., Resnick, M. B., Wands, J. & Cao, W. NADPH Oxidase NOX5-S and Nuclear Factor kappaB1 Mediate Acid-Induced Microsomal Prostaglandin E Synthase-1 Expression in Barrett's Esophageal Adenocarcinoma Cells. *Mol Pharmacol* **83**, 978–990, doi:10.1124/mol.111.083287.
8. Si, J. et al. NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. *J Biol Chem* **282**, 16244–16255, doi:10.1074/jbc.M700297200.
9. Li, D. & Cao, W. Role of intracellular calcium and NADPH oxidase NOX5-S in acid-induced DNA damage in Barrett's cells and Barrett's esophageal adenocarcinoma cells. *Am J Physiol Gastrointest Liver Physiol* **306**, G863–872, doi:10.1152/ajpgi.00321.2013.
10. Xia, D., Wang, D., Kim, S. H., Katoh, H. & DuBois, R. N. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. *Nat Med* **18**, 224–226, doi:10.1038/nm.2608.
11. Buttar, N. S. et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. *Gastroenterology* **122**, 1101–1112 (2002).
12. Jakobsson, P. J., Thoren, S., Morgenstern, R. & Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci USA* **96**, 7220–7225 (1999).
13. Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M. & Kudo, I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. *J Biol Chem* **275**, 32775–32782, https://doi.org/10.1074/jbc.M003504200 (2000).
14. Tanikawa, N. et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. *Biochem Biophys Res Commun* **291**, 884–889, https://doi.org/10.1016/j.bbrc.2002.06.6531 (2001).
15. Jung, T. J. et al. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat esophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. *Gut* **53**, 27–33 (2004).
16. von Rahden, B. H. et al. Expression of prostaglandin E synthase in Barrett's cancer. *Dis Esophagus* **21**, 304–308, https://doi.org/10.1111/j.1442-2050.2007.00801.x (2008).
17. Jaishwal, M., LaRussco, N. E. & Gores, G. J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. *Am J Physiol Gastrointest Liver Physiol* **281**, G626–634, https://doi.org/10.1152/ajpgi.2001.281.3.G626 (2001).
18. Lala, P. K. & Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. *Lancet Oncol* **2**, 149–156, https://doi.org/10.1016/S1470-2045(00)00256-4 (2001).
19. Burney, S., Caulfield, J. L., Niles, J. C., Wishnok, J. S. & Tannenbaum, S. R. The chemistry of DNA damage from nitric oxide and peroxynitrite. *Mutat Res* **424**, 37–49 (1999).
20. Clemmons, N. J. et al. Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. *Carcinogenesis* **31**, 1669–1675, https://doi.org/10.1093/carcin/bqj130 (2010).
21. Wilson, K. T., Fu, S., Ramanujam, K. S. & Meltzer, S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. *Cancer Res* **58**, 2929–2934 (1998).
22. Ohshima, H., Tatemichi, M. & Sawa, T. Chemical basis of inflammation-induced carcinogenesis. *Arch Biochem Biophys* **417**, 3–11 (2003).
23. Farhadi, A., Fields, J., Banan, A. & Keshavarzian, A. Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression towards esophageal cancer? *Am J Gastroenterol* **97**, 22–26 (2002).
24. Chanchal, S. K. et al. In vivo and in vitro protective effects of omeprazole against neuropsychiatric pain. *Sci Rep* **6**, 30007, https://doi.org/10.1038/srep30007 (2016).
25. Jaishwal, K. R. et al. Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). *Dis Esophagus* **20**, 256–264 (2007).
26. Hong, J., Li, D., Wands, J., Souza, R. & Cao, W. Role of NADPH oxidase NOX5-S, NF-kappaB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells. *Am J Physiol Cell Physiol* **305**, C1069–1079, https://doi.org/10.1152/ajpcell.00080.2013 (2013).
27. Liu, B. & Neufeld, A. H. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. *Arch Ophthalmol* **119**, 240–245 (2001).
28. Cao, W. et al. MAPK mediates PKC-dependent contraction of cartilage and lower esophageal sphincter circular smooth muscle. *Am J Physiol Gastrointest Liver Physiol* **285**, G86–95 (2003).
29. Brar, S. S. et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. *Am J Physiol Cell Physiol* **285**, C353–369 (2003).

Acknowledgements
This work was supported in part by NIDDK R01 DK080703.

Author contributions
D.L. performed majority of experiments and data analysis. D.D. obtained samples from patients. A.L. did the PPI experiments in FLO-1 cells. F.H. designed the clinical studies and obtained samples from patients. W.C. designed experiments, performed some experiments, and wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available this paper at https://doi.org/10.1038/s41598-019-52800-7.
Correspondence and requests for materials should be addressed to F.H. or W.C.
